Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
direct sale of 14,311 shares of Common Stock for a transaction value of approximately $457,000 between March 17, 2026 and March 19, 2026, as disclosed in the SEC Form 4 filing Transaction summary Metric Value Shares sold (direct) Transaction value Post-transaction shares (direct) Post-transaction value (direct ownership) $1.35 million Transaction value based on SEC Form 4 weighted average purchase price ($31.92); post-transaction value based on March 19, 2026 market close price. Key questions How does the size of this transaction compare to Ticho's historical trading activity? The 14,311-share sale exceeds the recent-period median sale size of 5,429.5 shares and the historical median of 7,073 shares across 16 prior sell transactions, reflecting a larger-than-typical disposition in the context of shrinking remaining holdings. What was the transactional context and mechanics behind the sale? The transaction involved the exercise of options followed by the imm
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics (STOK) had its price target raised by Canaccord Genuity Group Inc. from $36.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by BTIG Research. They now have a $39.00 price target on the stock.MarketBeat
- Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.MarketBeat
- Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Business Wire
- Stoke Therapeutics (STOK) had its price target raised by Wedbush from $36.00 to $38.00. They now have an "outperform" rating on the stock.MarketBeat
STOK
Earnings
- 3/16/26 - Beat
STOK
Sec Filings
- 3/24/26 - Form 4
- 3/20/26 - Form 144
- 3/19/26 - Form 4
- STOK's page on the SEC website